



Transglutaminase Newsletter April 2011

Open conformation TG2-ELISA-Kits – endotoxin free TG2

Dear valued customers,
Dear transglutaminase researchers,




Zedi would like to highlight our new [products](#):

Open tTGTM-ELISA-kits*

Upon substrate binding TG2 dramatically changes its structure.

By reacting TG2 with a novel irreversible inhibitor we could stabilize this open conformation, resulting in a superior antigen: open tTGTM. Open tTGTM renders novel epitopes accessible for autoantibody-binding, resulting in generally higher antibody titers.



Researchers of the University Tampere currently published their results using Open tTGTM-ELISAs for the analysis of selected sera in Journal of Clinical Immunology (Lindfors et al.,

09. March 2011, DOI 10.1007/s10875-011-9514-x). The authors conclude that *the Open tTGTM-ELISA constitutes a promising new non-invasive tool for the diagnostics and follow-up of celiac disease, especially in patients with diagnostic difficulties.*

E006 Open tTGTM tissue transglutaminase ELISA Kit (IgA)* [Info](#) 1 kit/96 wells 495 €

E007 Open tTGTM tissue transglutaminase ELISA Kit (IgG)* [Info](#) 1 kit/96 wells 495 €

*for R&D purposes

Endotoxin-free TG2-preparation

Human tissue transglutaminase preparation (T067) is now available with a certified endotoxin content < 4.5 EU/mg (< 9 EU/ml), rendering it suitable for cell culture and other preclinical** experiments

T067	Human tissue transglutaminase endotoxin-free	Info	250 µg	400 €
	(hTG2, produced in insect cells, endotoxin <4.5 EU/mg)		1 mg	1.200 €

**T067 is not intended for use in humans

For detailed information concerning our products please refer to our web site (www.zedira.com). Should you have any questions or queries about our products, please do not hesitate to contact us: contact@zedira.com. We are continuously enlarging our product portfolio in order to fulfill researchers' requirements in the field of transglutaminase R&D.

The newsletter is sent to known interested parties only. If you do not want to receive the Transglutaminase Newsletter anymore, please click here to [unsubscribe](#) your mail address. In case that you know potential new interested colleagues, please forward this e-mail.

This newsletter is published by:

Zedira GmbH
Roesslerstr. 83
64293 Darmstadt Germany

Phone: +49 6151 3251-00
Fax: +49 6151 3251-19
Web: www.zedira.com
E-Mail: contact@zedira.com

© 2011, Zedira GmbH